BR0312870A - Comprimido de liberação sustentada compreendendo reboxetina - Google Patents
Comprimido de liberação sustentada compreendendo reboxetinaInfo
- Publication number
- BR0312870A BR0312870A BR0312870-9A BR0312870A BR0312870A BR 0312870 A BR0312870 A BR 0312870A BR 0312870 A BR0312870 A BR 0312870A BR 0312870 A BR0312870 A BR 0312870A
- Authority
- BR
- Brazil
- Prior art keywords
- tablet
- sustained
- reboxetine
- release tablet
- sustained release
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Abstract
"COMPRIMIDO DE LIBERAçãO SUSTENTADA COMPREENDENDO REBOXETINA". Uma composição farmacêutica de liberação sustentada em uma forma de um comprimido para administração oral compreende um agente farmacêutico ativo tendo uma solubilidade não inferior a cerca de 10 mg/ml, dispersa em uma matriz compreendendo um polímero hidrófilo e um amido tendo uma resistência à tração de pelo menos cerca de 0,15 kN cm^ -2^ em uma fração sólida representativa do comprimido.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39844702P | 2002-07-25 | 2002-07-25 | |
US39842702P | 2002-07-25 | 2002-07-25 | |
US40660902P | 2002-08-28 | 2002-08-28 | |
US47938703P | 2003-06-18 | 2003-06-18 | |
PCT/US2003/023418 WO2004010998A1 (en) | 2002-07-25 | 2003-07-25 | Sustained-release tablet comprising reboxetine |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0312870A true BR0312870A (pt) | 2005-06-14 |
Family
ID=31192372
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0312870-9A BR0312870A (pt) | 2002-07-25 | 2003-07-25 | Comprimido de liberação sustentada compreendendo reboxetina |
Country Status (22)
Country | Link |
---|---|
US (2) | US20070196481A1 (pt) |
EP (2) | EP2172199A1 (pt) |
JP (2) | JP2005535681A (pt) |
KR (1) | KR100709807B1 (pt) |
CN (2) | CN1323663C (pt) |
AR (1) | AR040680A1 (pt) |
AT (1) | ATE456368T1 (pt) |
AU (2) | AU2003256834B2 (pt) |
BR (1) | BR0312870A (pt) |
CA (1) | CA2492424A1 (pt) |
DE (1) | DE60331153D1 (pt) |
HK (1) | HK1077753A1 (pt) |
IL (1) | IL166079A (pt) |
MX (1) | MXPA05001056A (pt) |
MY (1) | MY136318A (pt) |
NO (1) | NO20050094L (pt) |
NZ (1) | NZ537788A (pt) |
PL (1) | PL375738A1 (pt) |
RU (1) | RU2292873C2 (pt) |
TW (1) | TW200412962A (pt) |
WO (1) | WO2004010998A1 (pt) |
ZA (1) | ZA200500432B (pt) |
Families Citing this family (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7776314B2 (en) | 2002-06-17 | 2010-08-17 | Grunenthal Gmbh | Abuse-proofed dosage system |
US8679533B2 (en) * | 2002-07-25 | 2014-03-25 | Pharmacia Corporation | Pramipexole once-daily dosage form |
US20050226926A1 (en) * | 2002-07-25 | 2005-10-13 | Pfizer Inc | Sustained-release tablet composition of pramipexole |
US20040253305A1 (en) * | 2003-06-12 | 2004-12-16 | Luner Paul E. | Pharmaceutical compositions of atorvastatin |
WO2005005484A1 (ja) | 2003-07-11 | 2005-01-20 | Asahi Kasei Chemicals Corporation | 機能性澱粉粉末 |
WO2005011707A1 (en) | 2003-07-25 | 2005-02-10 | Warner Chilcott Company, Inc. | A doxycycline metal complex in a solid dosage form |
DE10336400A1 (de) | 2003-08-06 | 2005-03-24 | Grünenthal GmbH | Gegen Missbrauch gesicherte Darreichungsform |
DE102005005446A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Bruchfeste Darreichungsformen mit retardierter Freisetzung |
US8075872B2 (en) | 2003-08-06 | 2011-12-13 | Gruenenthal Gmbh | Abuse-proofed dosage form |
DE102004032051A1 (de) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform |
US20070048228A1 (en) | 2003-08-06 | 2007-03-01 | Elisabeth Arkenau-Maric | Abuse-proofed dosage form |
DE10361596A1 (de) | 2003-12-24 | 2005-09-29 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
US8591968B2 (en) | 2005-05-23 | 2013-11-26 | Kraft Foods Global Brands Llc | Edible composition including a delivery system for active components |
US8597703B2 (en) | 2005-05-23 | 2013-12-03 | Kraft Foods Global Brands Llc | Delivery system for active components as part of an edible composition including a ratio of encapsulating material and active component |
US8591973B2 (en) | 2005-05-23 | 2013-11-26 | Kraft Foods Global Brands Llc | Delivery system for active components and a material having preselected hydrophobicity as part of an edible composition |
US8389032B2 (en) * | 2005-05-23 | 2013-03-05 | Kraft Foods Global Brands Llc | Delivery system for active components as part of an edible composition having selected particle size |
US8591972B2 (en) | 2005-05-23 | 2013-11-26 | Kraft Foods Global Brands Llc | Delivery system for coated active components as part of an edible composition |
US20050112236A1 (en) | 2003-11-21 | 2005-05-26 | Navroz Boghani | Delivery system for active components as part of an edible composition having preselected tensile strength |
US8389031B2 (en) * | 2005-05-23 | 2013-03-05 | Kraft Foods Global Brands Llc | Coated delivery system for active components as part of an edible composition |
DE602005008721D1 (de) * | 2004-03-10 | 2008-09-18 | Ranbaxy Lab Ltd | Verfahren zur herstellung von festen dosierformen von amorphem valganciclovir-hydrochlorid |
DE102004032049A1 (de) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Gegen Missbrauch gesicherte, orale Darreichungsform |
KR101052436B1 (ko) | 2004-08-13 | 2011-07-29 | 베링거 인겔하임 인터내셔날 게엠베하 | 프라미펙솔 또는 약제학적으로 허용되는 이의 염을함유하는 연장 방출형 정제 제형, 이의 제조방법 및 이의용도 |
KR20070050081A (ko) * | 2004-08-13 | 2007-05-14 | 베링거 인겔하임 인터내셔날 게엠베하 | 프라미펙솔 또는 약제학적으로 허용되는 이의 염을포함하는 연장 방출형 펠렛 제형, 이의 제조방법 및 이의용도 |
KR100920856B1 (ko) * | 2004-11-30 | 2009-10-09 | (주)아모레퍼시픽 | 선택적 세로토닌 재흡수 억제제의 연장방출 제제 및 그제조방법 |
SG158869A1 (en) * | 2005-01-21 | 2010-02-26 | Warner Chilcott Co Llc | A tetracycline metal complex in a solid dosage form |
AU2005325930B2 (en) * | 2005-01-27 | 2012-01-19 | Alembic Limited | Extended release formulation of Levetiracetam |
DE102005005449A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
WO2007090883A1 (en) * | 2006-02-10 | 2007-08-16 | Boehringer Ingelheim International Gmbh | Extended release formulation |
WO2007090881A2 (en) * | 2006-02-10 | 2007-08-16 | Boehringer Ingelheim International Gmbh | Modified release formulation |
JP2009543780A (ja) * | 2006-07-11 | 2009-12-10 | ミューチュアル ファーマシューティカル カンパニー,インク. | 制御放出製剤およびキット |
KR20080007006A (ko) * | 2006-07-14 | 2008-01-17 | 주식회사 씨티씨바이오 | 용출편차가 감소한 염산파록세틴 서방정 |
CA2662542A1 (en) * | 2006-09-12 | 2008-03-20 | Glaxo Group Limited | Pharmaceutical composition comprising a plurality of mini-tablets comprising a factor xa inhibitor |
WO2008062446A2 (en) * | 2006-09-14 | 2008-05-29 | Alembic Limited | An extended release composition of levetiracetam, which exhibits no adverse food effect |
DE102007011485A1 (de) | 2007-03-07 | 2008-09-11 | Grünenthal GmbH | Darreichungsform mit erschwertem Missbrauch |
EP2155170A2 (en) | 2007-06-08 | 2010-02-24 | Addrenex Pharmaceuticals, Inc. | Extended release formulation and method of treating adrenergic dysregulation |
US20100172991A1 (en) * | 2007-06-08 | 2010-07-08 | Henry Joseph Horacek | Extended Release Formulation and Methods of Treating Adrenergic Dysregulation |
US9078824B2 (en) * | 2007-09-24 | 2015-07-14 | The Procter & Gamble Company | Composition and method of stabilized sensitive ingredient |
TWI454288B (zh) * | 2008-01-25 | 2014-10-01 | Gruenenthal Chemie | 藥物劑型 |
MX2008004268A (es) * | 2008-03-28 | 2009-09-28 | Posi Visionary Solutions Llp | Metoclopramida de liberacion prolongada de 24 horas. |
SI2273983T1 (sl) | 2008-05-09 | 2016-11-30 | Gruenenthal Gmbh | Postopek za pripravo intermediatne praškaste formulacije in končne trdne odmerne oblike z uporabo stopnje strjevanja z razprševanjem |
JP4746714B2 (ja) * | 2008-05-16 | 2011-08-10 | Axis株式会社 | 線維筋痛症治療用医薬組成物 |
US20100069389A1 (en) * | 2008-09-06 | 2010-03-18 | Bionevia Pharmaceuticals, Inc. | Novel forms of reboxetine |
WO2010030887A1 (en) | 2008-09-11 | 2010-03-18 | Catholic Healthcare West | Nicotinic attenuation of cns inflammation and autoimmunity |
WO2010044016A1 (en) * | 2008-10-17 | 2010-04-22 | Pfizer Limited | Novel uses for esreboxetine and racemic reboxetine |
WO2010083360A2 (en) * | 2009-01-16 | 2010-07-22 | Mutual Pharmaceutical Company, Inc. | Controlled-release formulations |
JP2012533585A (ja) | 2009-07-22 | 2012-12-27 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 酸化感受性オピオイドのための不正使用防止剤形 |
JP5667183B2 (ja) | 2009-07-22 | 2015-02-12 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 加熱溶融押出成型した制御放出性投与剤型 |
US20110052686A1 (en) * | 2009-09-03 | 2011-03-03 | Ranbaxy Laboratories Limited | Modified release lamotrigine tablets |
KR101137467B1 (ko) * | 2009-11-02 | 2012-04-20 | 안국약품 주식회사 | 테오브로민 함유 서방성 정제 |
US9579285B2 (en) | 2010-02-03 | 2017-02-28 | Gruenenthal Gmbh | Preparation of a powdery pharmaceutical composition by means of an extruder |
ES2486791T3 (es) | 2010-09-02 | 2014-08-19 | Grünenthal GmbH | Forma de dosificación resistente a la manipulación que comprende una sal inorgánica |
US9636303B2 (en) | 2010-09-02 | 2017-05-02 | Gruenenthal Gmbh | Tamper resistant dosage form comprising an anionic polymer |
CN103635096B (zh) | 2011-04-29 | 2016-08-17 | 洲际大品牌有限责任公司 | 被包封的酸、其制备方法及包括所述被包封的酸的咀嚼型胶基糖 |
AR087360A1 (es) | 2011-07-29 | 2014-03-19 | Gruenenthal Gmbh | Tableta a prueba de manipulacion que proporciona liberacion de farmaco inmediato |
US20130028972A1 (en) | 2011-07-29 | 2013-01-31 | Grunenthal Gmbh | Tamper-resistant tablet providing immediate drug release |
CN102319226B (zh) * | 2011-09-27 | 2013-04-24 | 南京正科制药有限公司 | 一种甲磺酸瑞波西汀微囊片及其制备方法 |
BR112014019988A8 (pt) | 2012-02-28 | 2017-07-11 | Gruenenthal Gmbh | Forma de dosagem resistente a socamento compreendendo um composto farmacologicamente ativo e um polímero aniônico |
ES2692944T3 (es) | 2012-04-18 | 2018-12-05 | Grünenthal GmbH | Forma de dosificación farmacéutica resistente a la manipulación y resistente a la descarga rápida de la dosis |
US10064945B2 (en) | 2012-05-11 | 2018-09-04 | Gruenenthal Gmbh | Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc |
US20140045801A1 (en) * | 2012-08-09 | 2014-02-13 | Mylan Inc. | Pramipexole transdermal delivery for severe headaches |
EP2732812A1 (de) | 2012-11-15 | 2014-05-21 | Aristo Pharma GmbH | Pramipexol-Retardtablettenformulierung |
CN103961325B (zh) * | 2013-02-03 | 2018-08-21 | 南京圣和药业股份有限公司 | 普拉克索片剂的制备方法和由此获得的片剂及其应用 |
KR102241112B1 (ko) * | 2013-02-28 | 2021-04-15 | 루핀 리미티드 | 특정한 체외 용해 프로파일 또는 약리역학 파라미터를 갖는 도네페질의 약제학적 조성물 |
US20160015698A1 (en) * | 2013-02-28 | 2016-01-21 | Lupin Limited | Pharmaceutical compositions of donepezil having specific in vitro dissolution profile or pharmacokinetics parameters |
CA2903757A1 (en) | 2013-03-07 | 2014-09-12 | Mindlab LLC | Pain medicine combination and uses thereof |
CN104146979A (zh) * | 2013-05-14 | 2014-11-19 | 上海星泰医药科技有限公司 | 盐酸普拉克索缓释片及制备方法 |
WO2014191396A1 (en) | 2013-05-29 | 2014-12-04 | Grünenthal GmbH | Tamper resistant dosage form with bimodal release profile |
BR112015026549A2 (pt) | 2013-05-29 | 2017-07-25 | Gruenenthal Gmbh | forma de dosagem à prova de violação contendo uma ou mais partículas |
CN105682643B (zh) | 2013-07-12 | 2019-12-13 | 格吕伦塔尔有限公司 | 含有乙烯-醋酸乙烯酯聚合物的防篡改剂型 |
CA2931553C (en) | 2013-11-26 | 2022-01-18 | Grunenthal Gmbh | Preparation of a powdery pharmaceutical composition by means of cryo-milling |
AU2015261060A1 (en) | 2014-05-12 | 2016-11-03 | Grunenthal Gmbh | Tamper resistant immediate release capsule formulation comprising Tapentadol |
AU2015266117A1 (en) | 2014-05-26 | 2016-11-24 | Grunenthal Gmbh | Multiparticles safeguarded against ethanolic dose-dumping |
MX2017013637A (es) | 2015-04-24 | 2018-03-08 | Gruenenthal Gmbh | Forma de dosificacion resistente a alteraciones con liberacion inmediata y resistencia contra la extraccion por solventes. |
US10842750B2 (en) | 2015-09-10 | 2020-11-24 | Grünenthal GmbH | Protecting oral overdose with abuse deterrent immediate release formulations |
US20190381056A1 (en) | 2018-06-17 | 2019-12-19 | Axsome Therapeutics, Inc. | Compositions for delivery of reboxetine |
US20200147093A1 (en) | 2018-10-15 | 2020-05-14 | Axsome Therapeutics, Inc. | Use of esreboxetine to treat nervous system disorders such as fibromyalgia |
KR20230055668A (ko) * | 2021-10-19 | 2023-04-26 | 단국대학교 천안캠퍼스 산학협력단 | 레복세틴을 유효성분으로 포함하는 근감소증의 예방 또는 치료용 조성물 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2887440A (en) * | 1957-08-12 | 1959-05-19 | Dow Chemical Co | Enteric coating |
JPS58403B2 (ja) * | 1975-07-24 | 1983-01-06 | 武田薬品工業株式会社 | L− アスコルビンサンセイザイノ セイゾウホウ |
ATE45735T1 (de) * | 1984-12-22 | 1989-09-15 | Thomae Gmbh Dr K | Tetrahydro-benzthiazole, deren herstellung und deren verwendung als zwischenprodukte oder als arnzneimittel. |
DE3447075A1 (de) * | 1984-12-22 | 1986-07-03 | Dr. Karl Thomae Gmbh, 7950 Biberach | Tetrahydro-benzthiazole, deren herstellung und deren verwendung als zwischenprodukte oder als arzneimittel |
US4886821A (en) * | 1987-01-27 | 1989-12-12 | American Home Products Corporation | 2-pyridinecarbothioamides and pharmaceutical compositions comprising the same useful as anti ulcer agents |
HU210264B (en) * | 1989-06-09 | 1995-03-28 | Upjohn Co | Process for producing amines of condensed ring-systems containing nitrogen and pharmaceutical compositions containing them |
US5472712A (en) * | 1991-12-24 | 1995-12-05 | Euroceltique, S.A. | Controlled-release formulations coated with aqueous dispersions of ethylcellulose |
US5968551A (en) * | 1991-12-24 | 1999-10-19 | Purdue Pharma L.P. | Orally administrable opioid formulations having extended duration of effect |
US5656296A (en) * | 1992-04-29 | 1997-08-12 | Warner-Lambert Company | Dual control sustained release drug delivery systems and methods for preparing same |
US5458887A (en) * | 1994-03-02 | 1995-10-17 | Andrx Pharmaceuticals, Inc. | Controlled release tablet formulation |
WO1997004752A1 (en) * | 1995-07-26 | 1997-02-13 | Duramed Pharmaceuticals, Inc. | Pharmaceutical compositions of conjugated estrogens and methods for their use |
US6117855A (en) * | 1996-10-07 | 2000-09-12 | Merck Sharp & Dohme Ltd. | Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent |
CA2211778A1 (en) * | 1997-08-14 | 1999-02-14 | Francois Carriere | Preparation of pregelatinized high amylose starch and debranched starch useful as an excipient for controlled release of active agents |
US6197339B1 (en) * | 1997-09-30 | 2001-03-06 | Pharmacia & Upjohn Company | Sustained release tablet formulation to treat Parkinson's disease |
GB9802201D0 (en) * | 1998-02-03 | 1998-04-01 | Cerestar Holding Bv | Free-flowable directly compressible starch as binder,disintegrant and filler for compresion tablets and hard gelatine capsules |
WO1999045924A1 (en) * | 1998-03-11 | 1999-09-16 | Smithkline Beecham Plc | Composition |
CA2371940C (en) * | 1999-03-31 | 2008-07-15 | Janssen Pharmaceutica N.V. | Pregelatinized starch in a controlled release formulation |
DE60035232T2 (de) * | 1999-07-01 | 2008-02-14 | Pharmacia & Upjohn Co. Llc, Kalamazoo | (S,S)-Reboxetin zur Behandlung von chronischem Müdigkeits-Syndrom |
CO5210862A1 (es) * | 1999-09-15 | 2002-10-30 | Alza Corp | Formas de dosificacion y metodos para proporcionar efectiva terapia de reboxetina con dosificacion de una vez al dia |
CA2384840A1 (en) * | 1999-09-30 | 2001-04-05 | The General Hospital Corporation | Use of pramipexole as a treatment for cocaine craving |
PT1257277E (pt) * | 2000-02-24 | 2005-09-30 | Pharmacia & Upjohn Co Llc | Novas combinacoes de farmacos |
US6277875B1 (en) * | 2000-07-17 | 2001-08-21 | Andrew J. Holman | Use of dopamine D2/D3 receptor agonists to treat fibromyalgia |
US20050226926A1 (en) * | 2002-07-25 | 2005-10-13 | Pfizer Inc | Sustained-release tablet composition of pramipexole |
-
2003
- 2003-07-24 US US10/626,379 patent/US20070196481A1/en not_active Abandoned
- 2003-07-24 AR AR20030102665A patent/AR040680A1/es unknown
- 2003-07-24 MY MYPI20032782A patent/MY136318A/en unknown
- 2003-07-25 RU RU2005101639/15A patent/RU2292873C2/ru not_active IP Right Cessation
- 2003-07-25 WO PCT/US2003/023418 patent/WO2004010998A1/en active Application Filing
- 2003-07-25 KR KR1020057001394A patent/KR100709807B1/ko not_active IP Right Cessation
- 2003-07-25 EP EP09178277A patent/EP2172199A1/en not_active Withdrawn
- 2003-07-25 DE DE60331153T patent/DE60331153D1/de not_active Expired - Fee Related
- 2003-07-25 MX MXPA05001056A patent/MXPA05001056A/es unknown
- 2003-07-25 CN CNB038178788A patent/CN1323663C/zh not_active Expired - Fee Related
- 2003-07-25 PL PL03375738A patent/PL375738A1/xx not_active Application Discontinuation
- 2003-07-25 AU AU2003256834A patent/AU2003256834B2/en not_active Ceased
- 2003-07-25 EP EP03771898A patent/EP1536791B1/en not_active Expired - Lifetime
- 2003-07-25 BR BR0312870-9A patent/BR0312870A/pt not_active IP Right Cessation
- 2003-07-25 AT AT03771898T patent/ATE456368T1/de not_active IP Right Cessation
- 2003-07-25 TW TW092120430A patent/TW200412962A/zh unknown
- 2003-07-25 JP JP2004524874A patent/JP2005535681A/ja not_active Ceased
- 2003-07-25 CN CNA2006101365501A patent/CN101125128A/zh active Pending
- 2003-07-25 CA CA002492424A patent/CA2492424A1/en not_active Abandoned
- 2003-07-25 NZ NZ537788A patent/NZ537788A/en unknown
-
2004
- 2004-12-30 IL IL166079A patent/IL166079A/en not_active IP Right Cessation
-
2005
- 2005-01-06 NO NO20050094A patent/NO20050094L/no not_active Application Discontinuation
- 2005-01-17 ZA ZA200500432A patent/ZA200500432B/xx unknown
- 2005-11-08 HK HK05109930A patent/HK1077753A1/xx not_active IP Right Cessation
-
2008
- 2008-12-04 AU AU2008252073A patent/AU2008252073A1/en not_active Abandoned
- 2008-12-19 US US12/339,212 patent/US20090143387A1/en not_active Abandoned
-
2009
- 2009-04-13 JP JP2009097049A patent/JP2009185051A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
EP1536791B1 (en) | 2010-01-27 |
NO20050094L (no) | 2005-02-24 |
MY136318A (en) | 2008-09-30 |
IL166079A (en) | 2012-08-30 |
CA2492424A1 (en) | 2004-02-05 |
HK1077753A1 (en) | 2006-02-24 |
AR040680A1 (es) | 2005-04-13 |
AU2008252073A1 (en) | 2009-01-08 |
CN101125128A (zh) | 2008-02-20 |
US20070196481A1 (en) | 2007-08-23 |
RU2005101639A (ru) | 2005-08-10 |
AU2003256834A1 (en) | 2004-02-16 |
EP2172199A1 (en) | 2010-04-07 |
ATE456368T1 (de) | 2010-02-15 |
RU2292873C2 (ru) | 2007-02-10 |
US20090143387A1 (en) | 2009-06-04 |
JP2005535681A (ja) | 2005-11-24 |
CN1323663C (zh) | 2007-07-04 |
AU2003256834B2 (en) | 2008-10-30 |
EP1536791A1 (en) | 2005-06-08 |
IL166079A0 (en) | 2006-01-15 |
WO2004010998A1 (en) | 2004-02-05 |
DE60331153D1 (de) | 2010-03-18 |
MXPA05001056A (es) | 2005-04-08 |
TW200412962A (en) | 2004-08-01 |
ZA200500432B (en) | 2006-07-26 |
NZ537788A (en) | 2007-11-30 |
KR100709807B1 (ko) | 2007-04-23 |
WO2004010998A8 (en) | 2005-01-27 |
CN1671383A (zh) | 2005-09-21 |
JP2009185051A (ja) | 2009-08-20 |
PL375738A1 (en) | 2005-12-12 |
KR20050062517A (ko) | 2005-06-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0312870A (pt) | Comprimido de liberação sustentada compreendendo reboxetina | |
BR0312960A (pt) | Composição de comprimido de liberação sustentada de pramipexol | |
EA200401009A1 (ru) | Предварительно желатинированный крахмал в композиции с контролируемым высвобождением | |
ATE333265T1 (de) | Oral anzuwendende schnell zerfallende feste darreichungsformen | |
CO5190672A1 (es) | Composicion para la dosificacion oral, de disolucion instantanea | |
CY1105648T1 (el) | Filbanserin για την θεραπεια εξτραπυραμιδικων διαταραχων κινησης | |
MX2008000099A (es) | Composiciones farmaceuticas de liberacion modificada novedosas, y procedimiento de preparacion de dichas composiciones. | |
BR0005938A (pt) | Composição de dosagem oral com libaraçãoprolongada | |
BR0212475A (pt) | Composições farmacêuticas | |
BRPI0414017A8 (pt) | pró-fármacos poliméricos de múltiplos braços | |
DE60205749D1 (de) | Oral anzuwendende arzneizusammensetzungen mit gesteuerter wirkstoffabgabe | |
CO5170471A1 (es) | Tabletas de liberacion modificada que incluyen amoxilina y clavulanato de potasio | |
RS50768B (sr) | Režim doziranja i farmaceutska formulacija za urgentnu zaštitu | |
PT1131050E (pt) | Formulacoes galenicas que se desintegram rapidamente na boca e metodo para as preparar | |
BR0112847A (pt) | Uso de uma forma de dosagem sólida | |
BR0013719A (pt) | Dosagem oral de liberaçâo controlada, apropriada para administração oral | |
DK1608349T3 (da) | Oralt tilförselssystem omfattende et antibakterielt og et antiinflammatorisk middel | |
ES2130081B1 (es) | Comprimido de maleato de trimebutina con recubrimiento laminar. | |
ATE442158T1 (de) | Oral verabreichte pharmazeutische zusammensetzungen mit einem abgabemittel in mikronisierter form | |
WO2005107702A3 (en) | Sustained release, mucoadhesive vaginal pharmaceutical compositions | |
BRPI0412430A (pt) | polipeptìdeo agonista do receptor de zot e zonulina | |
EA200702386A1 (ru) | Твердая фармацевтическая композиция для продолжительного высвобождения 1-(2,3,4-триметоксибензил)пиперазина и способ ее получения | |
EA200601283A1 (ru) | Фармацевтическая композиция с контролируемым высвобождением, содержащая нерастворимый в кислотах полимер и биоадгезивный полимер | |
PT1499278E (pt) | Forma de dosagem farmaceutica de libertacao imediata compreendendo tibolona polimorfa | |
WO2004096155A3 (en) | Tablets and methods for modified release of hydrophilic and other active agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B15K | Others concerning applications: alteration of classification |
Free format text: PARA: INT. CL. A61K 31/428, 9/20, 9/28, 31/5375, 31/4745; A61P 25/24 Ipc: A61K 31/428 (2011.01), A61K 9/20 (2011.01), A61K 9 |
|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 8A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2157 DE 08/05/2012. |